With regard to the incidence of brain metastasis (BM) in pts with ALK+ NSCLC who are naïve to ALKi, several retrospective studies have reported rates ranging from approximately 20 to 30 %, which is comparable to that observed in epidermal growth factor receptor (EGFR)-mutated NSCLC pts [14, 15]. This evidence concerns the gene ALK and non-small cell lung carcinoma.